MTX injection not superior to oral administration in juvenile idiopathic arthritis

News
Article

Injections of methotrexate were not superior to oral therapy in long-term treatment of patients with juvenile idiopathic arthritis, according to a new study, published in the May 30 online edition of Arthritis Care & Research.

Injections of methotrexate were not superior to oral therapy in long-term treatment of patients with juvenile idiopathic arthritis (JIA), according to a new study, published in the May 30 online edition of Arthritis Care & Research.

In the retrospective study, led by Araine Klein with Asklepios Klinik Sankt Augustin, in Germany, researchers reviewed 411 patients with JIA who received methotrexate (MTX) for at least 6 months. Patients in both the oral therapy and subcutaneous groups showed a high clinical response (73% for oral vs 72% for injection). In addition, 22% of patients who received oral MTX had at least 1 adverse event, compared to 27% in the subcutaneous group.

However, significantly more patients with subcutaneous application discontinued MTX because of adverse events (11%) compared to oral (5%).

“In this retrospective analysis, parenteral MTX was not superior to oral administration, regarding efficacy and tolerability,” the researchers wrote.

Newsletter

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Recent Videos
Related Content
© 2025 MJH Life Sciences

All rights reserved.